Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
A Midday Symposium to be Conducted at the 2019 ASHP Midyear Clinical Meeting & Exhibition
Tuesday, December 10, 2019, 11:30 AM - 1:00 PM PT
Mandalay Bay North Convention Center - South Pacific H, Lower Level
|Co-produced by ProCE and the Society of Infectious Diseases Pharmacists (SIDP).|
Globally, an overabundance of inappropriate antibiotic use in factories, farms,
improper use in people, and lack of consistent stewardship measures in health-systems
have compounded measures to address the rising bacterial resistance crisis. Multidrug-resistant
(MDR) gram-negative bacteria are particularly challenging for infectious diseases
professionals to address due to increased mechanisms to evade destruction and appearance
in the most vulnerable patients. Often emerging in the health-system setting, and
thus in the critically ill population, MDR gram-negative infections require immediate
attention. The Centers for Disease Control and Prevention (CDC) declared carbapenem-resistant
Enterobacteriaceae (CRE) an urgent threat – an entire class of bacteria which
have developed multiple enzymes to circumvent destruction by carbapenems.
This activity will review the current epidemiological resistance patterns of MDR gram-negative bacteria. Attendees will understand treatment strategies and patient selection criteria for the management of MDR gram-negative infections, including newly approved therapies and emerging treatment data. A discussion on incorporation of antimicrobial stewardship with a special focus on preserving newer therapies will provide additional insight into potential protocol development.
The target audience for this activity includes clinical pharmacists, community pharmacists, specialty pharmacists, and managed care professionals. At the completion of this activity, the participant will be better able to:
10:45 AM Doors Open
11:30 AM – 1:00 PM CE Activity
Pre-registration is encouraged, and will be used for planning purposes. Seating will be available on a first-come, first-served basis. On-site registration will be available, space permitting. Food and beverages are not provided at Midday Symposia. This ASHP policy considers the varied internal policies of commercial supporters related to the Physician Payments Sunshine Act. You are welcome to bring your lunch to the session.
Samuel L. Aitken, PharmD, MPH, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Director, PGY2 Infectious Diseases Pharmacy Residency
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Erin K. McCreary, PharmD, BCPS, BCIDP
Infectious Diseases Clinical Pharmacist
University of Pittsburgh Medical Center
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-504-L01-P has been assigned to this live knowledge-based activity (initial release date 12-10-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Aitken has received research grant funding from Melinta Therapeutics and Merck, and has served as an advisory board member for Merck, Paratek, and Shionogi. Dr. McCreary has served as a consultant for Cidara Therapeutics. A portion of grant funds received by ProCE from Merck will be used to compensate the faculty for this presentation.
This activity is supported by an educational grant from Merck.
Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.